# Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)

> **NCT01668784** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 821 (actual)

## Conditions studied

- Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma

## Interventions

- **BIOLOGICAL:** Nivolumab
- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT01668784
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10-09
- **Primary completion:** 2015-05-06
- **Final completion:** 2021-07-19
- **Target enrollment:** 821 (ACTUAL)
- **Last updated:** 2022-08-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01668784

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01668784, "Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01668784. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*